Teeft.i
Exploration
Accueil
Racine
Exploration
Accueil
Racine

Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « Teeft.i » - entrée « Cdai »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Cdad < Cdai < Cdai assessment  Facettes :

List of bibliographic references indexed by Cdai

Number of relevant bibliographic references: 54.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
002A06 (2013) S.-H. Park [États-Unis] ; I. Castrej N [États-Unis] ; J.-Y. Choe ; S.-K. Kim ; H.-J. Lee ; T. Pincus [États-Unis]THU0166 Associations of Formal Education Level with Rheumatoid Arthritis (RA) Core Data Set Variables and Indices in Korean Patients
002A07 (2013) I. Castrej N [États-Unis] ; M. Dougados [France] ; B. Combe [France] ; F. Guillemin [France] ; B. Fautrel [France] ; T. Pincus [États-Unis]THU0165 Predictive Value of Different Remission Criteria for a Good Functional Status Outcome: Results from the Espoir Cohort
002A08 (2013) I. Guseva ; N. Demidova ; N. Soroka [Russie] ; E. Panasyuk ; E. Luchikhina ; E. Fedorenko ; E. Alexandrova ; A. Novikov ; D. Trofimov [Russie] ; D. Karateev ; E. NasonovTHU0164 Polymorphism of Cytotoxic T-Lymphocyte Antigen 4 +49A/G is Associated with Refractoriness to Non-Biological Dmards in Rheumatoid Arthritis Patients
002A24 (2013) B. Möller [Suisse] ; A. Scherer [Suisse] ; P. M. Villiger [Suisse] ; A. Finckh [Suisse]THU0129 Anemia Adds Information to Predict Radiographic Progression of Erosions on All Levels Levels of Clinically Assessed Disease Activity
002B48 (2013) Y. Yabe [Japon] ; T. Kojima ; A. Kaneko ; Y. Kanayama ; Y. Hirano ; T. Shioura ; K. Saito [Japon] ; N. Asai ; T. Kobayakawa ; N. IshiguroSAT0143 Analysis of Patients Who Obtained Remission by Disease Activity Score After Tocilizumab Treatment But Still had Low Disease Activity by Clinical Disease Activity Index, and Examination of Points for Treatment Intensification
002B49 (2013) U. Klein [Suisse] ; E. Liang [Suisse] ; B. Vogel [Suisse] ; F. Kolbinger [Suisse] ; G. Bruin [Suisse] ; P. Lloyd [Suisse]SAT0142 Immunogenicity of the Novel Anti-Il-17A Antibody, Secukinumab, with Intravenous and Subcutaneous Dosing Regimens in Healthy Subjects and Patients
002B50 (2013) T. Kasama [Japon] ; M. Umemura [Japon] ; S. Isojima [Japon] ; T. Tokunaga [Japon] ; H. Tsukamoto [Japon] ; R. Yanai [Japon] ; H. Furuya [Japon] ; Y. Miwa [Japon]SAT0141 Correlation of Serum Macrophage Migration Inhibitory Factor Levels With Response to Tocilizumab Therapy in Patients with Rheumatoid Arthritis
002B52 (2013) T. Kojima [Japon] ; N. Takahashi [Japon] ; K. Funahashi [Japon] ; D. Kato [Japon] ; Y. Hattori [Japon] ; M. Hanabayashi [Japon] ; N. Asai [Japon] ; N. Ishiguro [Japon]SAT0139 Importance of Concomitant MTX Use During Treatment with Tocilizumab in Patients with Rheumatoid Arthritis
002B53 (2013) T. Okano ; T. Koike [Japon] ; M. Tada ; Y. Sugioka ; K. Mamoto ; K. Inui ; H. NakamuraSAT0138 Prediction of Response to Tocilizumab Using Biomarkers (Interleukin-1 Beta, D-Dimer and Fibrinogen) in Patients with Rheumatoid Arthritis
002B54 (2013) L. Xie ; M. C. Genovese [États-Unis] ; B. Zhu ; E. Edson-Heredia ; S. BanerjeeSAT0137 Early Clinical Improvements (Week 4) Predict Subsequent Clinical Response with Ixekizumab in Rheumatoid Arthritis Patients with Inadequate Response to tnf Inhibitors
002B55 (2013) R. Fleischmann [États-Unis] ; S. Fiore ; C. Fan ; D. Thompson [États-Unis]SAT0136 Sarilumab, a Fully Human Mab Against IL-6R Alpha, Subcutaneously-Administered Shows Significant Improvement in Ra Patients as Early as 2 Weeks: A Time to Event Analysis for Acr50 and Eular Good Response
002D73 (2013) C. Barnabe [Canada] ; N. X. Thanh ; A. Ohinmaa ; S. G. Barr [Canada] ; J. Homik [Canada] ; L. Martin [Canada] ; W. P. Maksymowych [Canada]FRI0416 Remission definitions affect cost savings estimates in anti-TNF treated rheumatoid arthritis patients
002D96 (2013) L. Harrold [États-Unis] ; G. Reed [États-Unis] ; R. Magner [États-Unis] ; A. Shewade [États-Unis] ; A. John [États-Unis] ; W. Reiss [États-Unis] ; J. Greenberg [États-Unis] ; J. Kremer [États-Unis]FRI0254 Comparative effectiveness of rituximab versus anti-tumor necrosis factor switching for rheumatoid arthritis patients
002D97 (2013) K. Katayama ; T. Sato ; T. Okubo ; R. Fukai ; H. Ito ; T. Kamishima [Japon]FRI0253 Increase of medium and large joint destruction in patients with rapid radiographic progression during treatment with tocilizumab
002E07 (2013) J. S. Smolen [Autriche] ; J. Wollenhaupt [Allemagne] ; P. Durez [Belgique] ; J. Gomez-Reino [Espagne] ; W. Grassi [Italie] ; M. Le Bars [France] ; C. Gaillez [France] ; C. Poncet [France] ; R. Westhovens [Belgique]FRI0242 Time to achieve remission and sustained remission for mtx-naïve patients with early ra treated with abatacept plus mtx versus mtx alone in the agree trial
002E22 (2013) D. Furst [États-Unis] ; K. L. Winthrop [États-Unis] ; K. A. Alexander ; A. Vashishtha ; S. F. Francom ; K. G. Saag [États-Unis]FRI0223 Long-term targeted safety event rates in ra patients following initiation of rituximab: interim analysis from sunstone registry
002E23 (2013) D. A. Pappas [États-Unis] ; A. John [États-Unis] ; J. R. Curtis [États-Unis] ; J. Kremer [États-Unis] ; W. Reiss ; A. Shewade [États-Unis] ; G. J. Silverman [États-Unis] ; J. Greenberg [États-Unis]FRI0222 Prevalence of low immunoglobulin levels and associations with rheumatoid arthritis factors
002E24 (2013) C. I. Daien ; S. Gailhac ; T. Mura [France] ; B. Combe ; M. Hahne ; J. MorelFRI0221 Tocilizumab increases regulatory t cells and nk cells cytotoxicity in rheumatoid arthritis patients
002E25 (2013) C. Codreanu ; I. Ancuta ; R. Ionescu [Roumanie]FRI0220 Sustained clinical efficacy after multiple courses of rituximab in rheumatoid arthritis patients with inadequate response to tumour necrosis factor inhibitors: 2-year data from the repeat (repeated courses in routine clinical practice) study
002E26 (2013) B. Missler-Karger [Allemagne] ; M. Leu ; M. A. Raboisson ; B. Pilstrom [Suède]FRI0219 Disease severity, no steroid use and type ii diabetes predict response to anakinra (kineret®) in patients with rheumatoid arthritis
002E27 (2013) A. Ogata [Japon]FRI0218 Normalization of c-reactive protein within the first 8 weeks is a predictive factor for the effectiveness of subcutaneous tocilizumab monotherapy in japanese rheumatoid arthritis patients: results from the musashi study

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Teeft.i -k "Cdai" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Teeft.i  \
                -Sk "Cdai" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Teeft.i
   |clé=    Cdai
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021